1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Briese, L. Willbold, D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Bmc Struct.Biol. 1472-6807 3 3 3 10.1186/1472-6807-3-3 12734017 Structure determination of human Lck unique and SH3 domains by nuclear magnetic resonance spectroscopy. 2003 10.2210/pdb1kik/pdb pdb_00001kik 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 6411.063 PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK 2.7.1.112 SH3 DOMAIN (RESIDUES 64-120) 1 man polymer P56-LCK, LSK, T cell-specific protein-tyrosine kinase no no NLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN NLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia Escherichia coli sample 9606 Homo sapiens 511693 Escherichia coli BL21 BL21 plasmid pGEX-6P-2 database_2 pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2001-12-12 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession Sh3-Sh2 Domain Fragment Of Human P56-Lck Tyrosine Kinase Complexed With The 10 Residue Synthetic Phosphotyrosyl Peptide Tegqpyqpqpa Complex (Kinase/Peptide) Sh3 Domain Of Human Lck Tyrosine Kinase Sh2 (Src Homology-2) Domain Of Human P56-Lck Tyrosine Kinase Complexed With The 11 Residue Phosphotyrosyl Peptide Epqpyeeipiyl Complex (Kinase/Peptide) Structural Analysis Of The Lymphocyte-Specific Kinase Lck In Complex With Non-Selective and Src Family Selective Kinase Inhibitors RCSB Y RCSB 2001-12-03 REL REL structures with the lowest energy 150 25 3D_13C-separated_NOESY 3D_15N-separated_NOESY HNHA 20 6.5 1 atm 298 K 20 6.5 1 atm 298 K simulated annealing 1 lowest energy 1,6mM Lck unique and SH3 domains, U-15N,13C; 20 mM sodium acetate 90% H2O/10% D2O 1mM Lck unique and SH3 domains, U-15N; 20 mM sodium acetate 90% H2O/10% D2O collection VNMR 5.3b processing PROSA 2.9 data analysis XEASY 1.3.13 structure solution ARIA 1.0 refinement CNS 1.0 750 Varian INOVA 600 Varian INOVA ASN 64 n 1 ASN 64 A LEU 65 n 2 LEU 65 A VAL 66 n 3 VAL 66 A ILE 67 n 4 ILE 67 A ALA 68 n 5 ALA 68 A LEU 69 n 6 LEU 69 A HIS 70 n 7 HIS 70 A SER 71 n 8 SER 71 A TYR 72 n 9 TYR 72 A GLU 73 n 10 GLU 73 A PRO 74 n 11 PRO 74 A SER 75 n 12 SER 75 A HIS 76 n 13 HIS 76 A ASP 77 n 14 ASP 77 A GLY 78 n 15 GLY 78 A ASP 79 n 16 ASP 79 A LEU 80 n 17 LEU 80 A GLY 81 n 18 GLY 81 A PHE 82 n 19 PHE 82 A GLU 83 n 20 GLU 83 A LYS 84 n 21 LYS 84 A GLY 85 n 22 GLY 85 A GLU 86 n 23 GLU 86 A GLN 87 n 24 GLN 87 A LEU 88 n 25 LEU 88 A ARG 89 n 26 ARG 89 A ILE 90 n 27 ILE 90 A LEU 91 n 28 LEU 91 A GLU 92 n 29 GLU 92 A GLN 93 n 30 GLN 93 A SER 94 n 31 SER 94 A GLY 95 n 32 GLY 95 A GLU 96 n 33 GLU 96 A TRP 97 n 34 TRP 97 A TRP 98 n 35 TRP 98 A LYS 99 n 36 LYS 99 A ALA 100 n 37 ALA 100 A GLN 101 n 38 GLN 101 A SER 102 n 39 SER 102 A LEU 103 n 40 LEU 103 A THR 104 n 41 THR 104 A THR 105 n 42 THR 105 A GLY 106 n 43 GLY 106 A GLN 107 n 44 GLN 107 A GLU 108 n 45 GLU 108 A GLY 109 n 46 GLY 109 A PHE 110 n 47 PHE 110 A ILE 111 n 48 ILE 111 A PRO 112 n 49 PRO 112 A PHE 113 n 50 PHE 113 A ASN 114 n 51 ASN 114 A PHE 115 n 52 PHE 115 A VAL 116 n 53 VAL 116 A ALA 117 n 54 ALA 117 A LYS 118 n 55 LYS 118 A ALA 119 n 56 ALA 119 A ASN 120 n 57 ASN 120 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A O ILE 111 A O ILE 48 A N TRP 98 A N TRP 35 A O GLN 101 A O GLN 38 A N ARG 89 A N ARG 26 A O LEU 88 A O LEU 25 A N VAL 66 A N VAL 3 A N ILE 67 A N ILE 4 A O ALA 117 A O ALA 54 1 A A H O LEU PHE 80 110 1.56 2 A A H O LEU PHE 80 110 1.60 6 A A H O LEU PHE 80 110 1.57 7 A A H O LEU PHE 80 110 1.60 8 A A H O LEU PHE 80 110 1.56 11 A A H O LEU PHE 80 110 1.58 14 A A H O LEU PHE 80 110 1.58 17 A A H O LEU PHE 80 110 1.56 18 A A H O LEU PHE 80 110 1.59 20 A A H O LEU PHE 80 110 1.55 23 A A H O LEU PHE 80 110 1.57 24 A A H O LEU PHE 80 110 1.58 25 A A H O LEU PHE 80 110 1.57 1 A PRO 74 -37.21 126.22 1 A SER 102 -49.35 167.90 1 A PRO 112 -52.64 108.34 1 A ASN 114 -98.97 30.36 1 A LYS 118 -39.67 139.25 1 A ALA 119 -69.35 54.44 2 A PRO 74 -37.65 120.45 2 A SER 102 -49.98 167.81 2 A PRO 112 -53.62 109.77 2 A ASN 114 -99.12 30.87 2 A LYS 118 -39.59 139.09 2 A ALA 119 -69.01 53.98 3 A PRO 74 -36.34 132.43 3 A SER 75 -130.53 -43.65 3 A GLN 93 -140.25 36.70 3 A LYS 118 -39.53 138.91 3 A ALA 119 -69.25 54.38 4 A PRO 74 -37.22 129.36 4 A SER 102 -49.08 167.17 4 A LYS 118 -39.59 139.03 4 A ALA 119 -69.19 54.51 5 A PRO 74 -37.14 133.58 5 A SER 102 -49.51 166.66 5 A LYS 118 -39.36 137.98 5 A ALA 119 -69.08 54.51 6 A PRO 74 -36.83 127.56 6 A SER 102 -49.42 167.64 6 A LYS 118 -39.46 139.48 6 A ALA 119 -69.84 53.82 7 A PRO 74 -36.27 131.69 7 A SER 75 -130.10 -43.22 7 A SER 102 -49.41 168.40 7 A LYS 118 -39.58 138.94 7 A ALA 119 -69.61 54.28 8 A PRO 74 -37.04 122.14 8 A SER 102 -49.57 167.43 8 A LYS 118 -39.65 140.43 8 A ALA 119 -69.80 50.89 9 A PRO 74 -37.72 120.02 9 A SER 102 -49.86 167.75 9 A ASN 114 -98.81 31.63 9 A LYS 118 -39.40 138.58 9 A ALA 119 -69.56 54.41 10 A PRO 74 -36.92 124.46 10 A SER 102 -49.69 167.70 10 A LYS 118 -39.38 138.51 10 A ALA 119 -69.32 54.77 11 A PRO 74 -36.77 123.93 11 A SER 102 -49.25 167.71 11 A PRO 112 -51.68 109.95 11 A ASN 114 -98.69 30.37 11 A LYS 118 -39.47 139.48 11 A ALA 119 -69.68 53.95 12 A PRO 74 -35.95 131.38 12 A SER 75 -130.01 -43.48 12 A SER 102 -49.70 167.37 12 A LYS 118 -39.52 138.76 12 A ALA 119 -69.67 53.78 13 A PRO 74 -37.40 123.19 13 A SER 102 -49.75 166.96 13 A LYS 118 -39.42 139.32 13 A ALA 119 -69.94 54.00 14 A PRO 74 -36.73 126.81 14 A GLU 96 -49.63 -19.95 14 A SER 102 -49.73 168.01 14 A ASN 114 -98.99 30.83 14 A LYS 118 -39.38 139.63 15 A PRO 74 -37.90 123.71 15 A SER 102 -49.82 166.54 15 A LYS 118 -39.53 139.40 15 A ALA 119 -69.59 53.47 16 A PRO 74 -35.03 126.73 16 A LYS 118 -39.47 138.24 16 A ALA 119 -68.80 54.89 17 A PRO 74 -36.48 128.22 17 A SER 102 -49.21 167.58 17 A LYS 118 -39.48 140.79 18 A PRO 74 -37.12 125.86 18 A SER 102 -49.54 167.96 18 A ASN 114 -99.84 31.70 18 A LYS 118 -39.50 139.27 18 A ALA 119 -69.48 54.19 19 A PRO 74 -39.41 112.93 19 A SER 102 -49.77 166.34 19 A LYS 118 -39.33 139.17 19 A ALA 119 -69.93 54.54 20 A PRO 74 -36.61 125.63 20 A SER 102 -49.73 167.43 20 A LYS 118 -39.60 138.21 20 A ALA 119 -68.89 54.69 21 A PRO 74 -35.91 128.72 21 A GLU 96 -49.84 -19.99 21 A SER 102 -49.91 167.95 21 A LYS 118 -39.57 140.72 22 A PRO 74 -37.08 127.28 22 A SER 102 -49.52 167.72 22 A LYS 118 -39.39 140.15 23 A PRO 74 -36.40 132.93 23 A SER 75 -130.28 -42.48 23 A GLN 93 -140.63 37.51 23 A LYS 118 -39.49 138.84 23 A ALA 119 -69.47 54.31 24 A PRO 74 -37.09 128.71 24 A SER 102 -49.25 168.00 24 A ASN 114 -99.08 30.81 24 A LYS 118 -39.56 139.33 24 A ALA 119 -69.42 54.56 25 A PRO 74 -36.66 129.87 25 A GLN 93 -141.47 37.39 25 A SER 102 -49.77 167.81 25 A LYS 118 -39.55 140.47 SH3 Domain of Lymphocyte Specific Kinase (LCK) 1 N N TRANSFERASE SH3 DOMAIN, TYROSINE KINASE, SIGNAL TRANSDUCTION, LCK, TRANSFERASE LCK_HUMAN UNP 1 63 P06239 NLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN 63 119 1KIK 64 120 P06239 A 1 1 57 5 anti-parallel anti-parallel anti-parallel anti-parallel A GLU 108 A GLU 45 A PRO 112 A PRO 49 A TRP 97 A TRP 34 A SER 102 A SER 39 A GLN 87 A GLN 24 A GLU 92 A GLU 29 A LEU 65 A LEU 2 A ALA 68 A ALA 5 A VAL 116 A VAL 53 A LYS 118 A LYS 55